Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/18/2915001/0/en/Junshi-Biosciences-Announces-the-Acceptance-of-the-Supplemental-New-Drug-Application-for-Toripalimab-Combined-with-Bevacizumab-for-the-First-Line-Treatment-of-Advanced-Hepatocellul.html
https://www.globenewswire.com/news-release/2024/06/25/2903696/0/en/Junshi-Biosciences-Announces-Approval-of-the-sNDA-for-Toripalimab-for-the-1st-Line-Treatment-of-Advanced-TNBC.html
https://www.globenewswire.com/news-release/2024/06/18/2900142/0/en/Junshi-Biosciences-Announces-Approval-of-the-sNDA-for-Toripalimab-for-the-1st-Line-Treatment-of-Small-Cell-Lung-Cancer.html
https://www.fiercepharma.com/pharma/junshi-coherus-pd-1-inhibitor-loqtorzi-scores-liver-cancer-trial
https://www.globenewswire.com/news-release/2024/06/12/2897253/0/en/Junshi-Biosciences-Announces-Phase-3-Study-of-Toripalimab-Combined-with-Bevacizumab-for-the-First-line-Treatment-of-Advanced-Hepatocellular-Carcinoma-Meets-Primary-Endpoint.html
https://www.globenewswire.com/news-release/2024/04/25/2869233/0/en/Junshi-Biosciences-Announces-NDA-Acceptance-in-Hong-Kong-for-Toripalimab.html
https://www.globenewswire.com/news-release/2024/04/07/2858828/0/en/Junshi-Biosciences-Announces-Approval-of-the-sNDA-for-Toripalimab-for-the-1st-Line-Treatment-of-Renal-Cancer.html
https://www.globenewswire.com//news-release/2024/02/02/2822598/0/en/Junshi-Biosciences-Announces-Toripalimab-s-NDA-Accepted-by-the-Singapore-Health-Sciences-Authority.html
https://www.globenewswire.com//news-release/2024/01/18/2811217/0/en/Junshi-Biosciences-Announces-JAMA-Publication-of-Results-from-NEOTORCH-a-Randomized-Phase-3-Trial-of-Perioperative-Toripalimab-plus-Chemotherapy-for-Patients-with-Resectable-Non-Sm.html
https://endpts.com/coherus-exits-tigit-deal-with-junshi-three-months-after-surface-oncology-buyout/